In short

Compounding a copy of an approved drug is restricted. A shortage designation is one of the routes that opens it, which is why widespread compounding of GLP-1.

By Alsen Walker · Updated October 6, 2026

Compounding a copy of an approved drug is restricted. A shortage designation is one of the routes that opens it, which is why widespread compounding of GLP-1 medications followed supply constraints. When shortage status changes, so does what compounders may lawfully do, and that has changed.

Check the current position before acting on anything written about this. FDA publishes shortage status directly, and it has moved for these products. Articles, forum posts and seller claims lag behind, sometimes by a long way, and sellers have a reason not to update.

For the wider picture on compounded products and how to check a supplier, see Compounded GLP-1s: What They Are and How to Check a Supplier.

Why shortage status controls this

Federal law restricts compounding drugs that are essentially copies of commercially available approved products. The reasoning is straightforward: if an approved product is available, a compounded copy circumvents the approval system.

When a product is listed as in shortage, that restriction eases, on the basis that patients need access to something.

So the permission was always conditional on the shortage, and always temporary in principle.

What changes when a shortage resolves

The basis for compounding copies falls away. Regulators have generally allowed transition periods rather than immediate cessation, and the specifics differ by product and by facility type.

For patients this means a supply that was available may stop being available, sometimes with limited notice from the provider.

If you are using a compounded product, this is worth asking your provider about directly rather than waiting to find out.

The workarounds that appear

Two are worth recognising because both have been the subject of regulatory attention.

Personalisation. Adding an ingredient, or offering doses not commercially available, to argue the product is not a copy. Whether that holds legally depends on the specifics and on whether the variation has a clinical rationale for that patient.

Salt forms. Selling semaglutide sodium or acetate rather than the base. These are different substances from the approved active ingredient, and FDA has raised concerns about them.

Neither converts an unapproved product into an approved one, and both are areas where enforcement and litigation have been active.

What to ask your provider

Whether they are still supplying compounded product and on what legal basis.

Which pharmacy or outsourcing facility prepares it.

Exactly which substance and concentration you are receiving, in writing.

What happens to your supply if the position changes again.

Whether they can help you transition to an approved product, and what that would cost.

Planning for a transition

If you are moving from compounded to approved product, dosing is not a simple transfer, since concentrations and presentations differ. That is a prescriber decision.

Start the coverage conversation early. An approved product needs a prior authorization, and that takes time you may not have if your supply stops abruptly.

Frequently asked questions

Can compounders still make these?
Depends on current shortage status and guidance. Verify directly with FDA rather than relying on any article.

Where do I check?
FDA publishes drug shortage status. That is the authoritative source.

My provider says it is still fine. Is it?
They may be correct, and they also have a commercial interest. Verify independently.

What if my supply stops?
Speak to a prescriber about transitioning to an approved product, and start the authorization early.

Is a personalised formulation exempt?
A contested area. Variation without clinical rationale has attracted regulatory attention.

Does this affect what I already have?
Ask your prescriber. Do not simply continue without knowing what you are taking.

Alsen Walker is a health writer and researcher at GLP1Hub with five years of experience researching and writing health and medical content. He works in a medical-field role alongside his undergraduate studies. At GLP1Hub he researches GLP-1 weight loss programs, pricing and insurance rules, and checks claims against FDA prescribing information, published clinical trials and official government sources. Alsen is not a physician, and his articles are general information, not medical advice.